# A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

Study · id `cardio:ct-nct07229937` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07229937](<https://clinicaltrials.gov/study/NCT07229937>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07229937

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 189 participants.

## Technical summary

Registry record NCT07229937. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2026-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 189 participants (planned count; ClinicalTrials.gov record NCT07229937, source copy `cardio:ctgov-nct07229937-2025-12-12`, retrieved 2026-10-31)
- Started: 2025-11-25 (actual) (ClinicalTrials.gov record NCT07229937, source copy `cardio:ctgov-nct07229937-2025-12-12`, retrieved 2026-10-31)
- Primary completion: 2026-08 (anticipated) (ClinicalTrials.gov record NCT07229937, source copy `cardio:ctgov-nct07229937-2025-12-12`, retrieved 2026-10-31)
- Completion: 2026-08 (anticipated) (ClinicalTrials.gov record NCT07229937, source copy `cardio:ctgov-nct07229937-2025-12-12`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07229937, source copy `cardio:ctgov-nct07229937-2025-12-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07229937-2025-12-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
- Condition: Hyperlipidemia
- Intervention (Drug): HRS-1301
- Intervention (Drug): HRS-1301
- Intervention (Drug): HRS-1301
- Intervention (Drug): HRS-1301
- Intervention (Drug): Placebo
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: b03ec627de950b2ca1bfbfba4f9cc117c7eb1aca6184c69ad5cdc4ba9cbc2cb4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
